American Federation of Aging Research
invite you to a free webinar
The State of Gerotherapeutics:
Next-Gen Interventions to Extend Healthy Living
Monday, September 22, 2025
3-4 pm ET / 12-1pm PT
RSVP
featuring
Dana G. Smith
Health Reporter, The New York Times
Moderator
Nir Barzilai, MD
President, Academy of Health and Lifespan Research; AFAR Board Member and multiple grantee; Co-Principal Investigator, TAME Trial; Author, Age Later: Health Span, Life Span, and the New Science of Longevity
Panelist
Rafael de Cabo, PhD
Chief, Translational Gerontology Branch of the National Institute on Aging; Senior Investigator, Experimental Gerontology Section of the National Institutes of Health (NIH); AFAR Irving S. Wright Award Winner; Academy for Health and Lifespan Research Member
Panelist
Sara Espinoza, MD, MSc
Director, Center for TranslationalGeroscience at Cedars-Sinai Medical Center;
AFAR Board Member; Academy for Health and Lifespan Member
Panelist
Kristen Fortney, PhD
CEO and Co-Founder, BioAGE Labs; AFAR grantee
Panelist
Carolina Solis-Herrara, MD
Principal Investigator, SGLT2 Inhibitors and Aging Biomarkers Trial at UT Health Barshop Institute; Division Chief & Associate Professor,Division of Endocrinology, UT Health San Antonio School of Medicine
Panelist
Science-backed gerotherapeutics can target the biological mechanisms of aging in order to extend health and prevent and delay diseases and conditions common to our bodies as we grow older. Bolstered by discoveries at academic labs and emerging biotech companies, these innovations are poised to move from bench to bedside.
And from The New York Times to WIRED, the BBC to Netflix, National Geographic to JAMA and beyond, the promise of these age-targeting therapeutic interventions — such as Metformin, Rapamycin, and even GLP-1s — continues to generate media attention and tantalize consumers. At the same time, an explosion of “anti-aging” supplements and claims of biohacking “remedies” from questionable sources is muddying the waters.
Amid this buzz, how do we distinguish the hype from the hope and the science from the spin?
To provide a reality check on the readiness and intentions of gerotherapeutics, AFAR and the Academy for Health and Lifespan Research (AHLR) invite you to a free webinar on the current state of existing and emerging drug interventions to extend healthspan, our years of health as we grow older.
Renowned leaders from the academic, clinical, and private sectors will:
-
Clarify how both repurposing existing drugs and developing novel compounds can extend healthspan
-
Unpack the need for human trials, the importance of an FDA indication for aging, as well as the risks in off-label use and harm of radical life extension claims
-
Counter myths and misinformation with accurate expectations and language
-
Confront barriers that impact gerotherapeutics from safely entering the market
-
Explore how drug and lifestyle interventions work together to help us live healthier, longer at any age
The expert-backed conversation also will touch on hot topics such as the federal path to drug discovery, the momentum of the private biotech sector, the emerging use of GLP1s and SGL2s to extend healthspan, and what’s needed next to bring these promising therapeutics to consumers and clinicians soon.
Please join us for an expert-led conversation on the promise of therapeutics to help us all live healthier, longer!